Nicoline Hoogerbrugge

List of Publications by Year
in descending order

308	16,840	16450 64	20358 116
papers	citations	h-index	g-index

314	314	314	18595
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Healthcare professionalsâ€™ perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups. Familial Cancer, 2023, 22, 1-11.	1.9	3
2	Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis. Gynecologic Oncology, 2022, 164, 221-230.	1.4	11
3	Genetic Cancer Susceptibility in Adolescents and Adults 25ÂYears or Younger With Colorectal Cancer. Gastroenterology, 2022, 162, 969-974.e6.	1.3	2
4	Gastric cancer genetic predisposition and clinical presentations: Established heritable causes and potential candidate genes. European Journal of Medical Genetics, 2022, 65, 104401.	1.3	10
5	Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors. Supportive Care in Cancer, 2022, 30, 3409-3418.	2.2	1
6	Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. Journal of Clinical Oncology, 2022, 40, 1879-1891.	1.6	25
7	Solving the genetic aetiology of hereditary gastrointestinal tumour syndromesâ€“ a collaborative multicentre endeavour within the project Solve-RD. European Journal of Medical Genetics, 2022, 65, 104475.	1.3	2
8	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. American Journal of Human Genetics, 2022, 109, 953-960.	6.2	23
9	Catch them if you are aware: PTEN postzygotic mosaicism in clinically suspicious patients with PTEN Hamartoma Tumour Syndrome and literature review. European Journal of Medical Genetics, 2022, , 104533.	1.3	4
10	The yield and effectiveness of breast cancer surveillance in women with <scp>PTEN</scp> Hamartoma Tumor Syndrome. Cancer, 2022, 128, 2883-2891.	4.1	4
11	A review on ageâ€related cancer risks in <scp>PTEN</scp> hamartoma tumor syndrome. Clinical Genetics, 2021, 99, 219-225.	2.0	42
12	Somatic Nonepigenetic Mismatch Repair Gene Aberrations Underly Most Mismatch Repairâ€“Deficient Lynch-Like Tumors. Gastroenterology, 2021, 160, 1414-1416.e3.	1.3	13
13	No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Journal of Cardiology, 2021, 77, 570-575.	1.9	3
14	RNF43 mutation analysis in serrated polyposis, sporadic serrated polyps and Lynch syndrome polyps. Histopathology, 2021, 78, 749-758.	2.9	10
15	Continue rare cancers collaboration with European Reference Networks after Brexit. Lancet, The, 2021, 397, 793.	13.7	2
16	European Reference Networks: challenges and opportunities. Journal of Community Genetics, 2021, 12, 217-229.	1.2	21
17	Breast cancer surveillance in women with PTEN Hamartoma Tumour Syndrome (PHTS). Breast, 2021, 56, S38.	2.2	0
18	Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome. Cancers, 2021, 13, 2345.	3.7	3

#	Article	IF	Citations
19	A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report. European Journal of Human Genetics, 2021, 29, 1354-1358.	2.8	9
20	Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases. European Journal of Human Genetics, 2021, 29, 1325-1331.	2.8	49
21	Universal genetic assessment for women with ovarian cancer not yet achieved: the promises of universal tumor DNA testing. Gynecologic Oncology Reports, 2021, 38, 100825.	0.6	0
22	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	10.7	58
23	Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers. JAMA Oncology, 2021, 7, 1203.	7.1	27
24	Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. Gynecologic Oncology, 2021, 163, 371-377.	1.4	2
25	Red flags for early recognition of adult patients with PTEN Hamartoma Tumour Syndrome. European Journal of Medical Genetics, 2021, 64, 104364.	1.3	7
26	Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. European Journal of Medical Genetics, 2021, 64, 104350.	1.3	22
27	Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition. Journal of the National Cancer Institute, 2020, 112, 161-169.	6.3	47
28	Response to Tomao, Panici, and Tomao. Journal of the National Cancer Institute, 2020, 112, 425-425.	6.3	0
29	Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis. European Journal of Human Genetics, 2020, 28, 277-286.	2.8	22
30	â€œPatient Journeysâ€: improving care by patient involvement. European Journal of Human Genetics, 2020, 28, 141-143.	2.8	18
31	Candidate Gene Discovery in Hereditary Colorectal Cancer and Polyposis Syndromesâ€“Considerations for Future Studies. International Journal of Molecular Sciences, 2020, 21, 8757.	4.1	7
32	Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397.	10.7	237
33	Monoallelic NTHL1 Loss-of-Function Variants and Risk of Polyposis and Colorectal Cancer. Gastroenterology, 2020, 159, 2241-2243.e6.	1.3	20
34	Recommendations on Surveillance for Differentiated Thyroid Carcinoma in Children with PTEN Hamartoma Tumor Syndrome. European Thyroid Journal, 2020, 9, 234-242.	2.4	14
35	Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. European Journal of Human Genetics, 2020, 28, 1387-1393.	2.8	63
36	Evaluation of yield and experiences of ageâ€related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome. International Journal of Cancer, 2020, 147, 2150-2158.	5.1	15

#	Article	IF	Citations
37	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	2.5	24
38	TRIM28 haploinsufficiency predisposes to Wilms tumor. International Journal of Cancer, 2019, 145, 941-951.	5.1	45
39	Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome. Oncogene, 2019, 38, 3743-3755.	5.9	20
40	Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2breast cancer families. Journal of Medical Genetics, 2019, 56, 581-589.	3.2	35
41	De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability, Short Stature, and Facial Dysmorphism. American Journal of Human Genetics, 2019, 104, 758-766.	6.2	34
42	Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression. Arthritis Research and Therapy, 2019, 21, 50.	3.5	25
43	Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype. Cancer Cell, 2019, 35, 256-266.e5.	16.8	123
44	Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling. Acta OncolÃ³gica, 2019, 58, 175-181.	1.8	6
45	Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. Familial Cancer, 2019, 18, 281-284.	1.9	17
46	PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. Translational Oncology, 2019, 12, 361-367.	3.7	33
47	High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer. Clinical Cancer Research, 2018, 24, 1594-1603.	7.0	52
48	A patient decision aid for riskâ€reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing. Health Expectations, 2018, 21, 659-667.	2.6	17
49	Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility. Journal of Medical Genetics, 2018, 55, 669-674.	3.2	37
50	Peritoneal carcinomatosis after riskâ€reducing surgery in BRCA1/2 mutation carriers. Cancer, 2018, 124, 952-959.	4.1	27
51	Self-compassion, physical fitness and climacteric symptoms in oophorectomized BRCA1/2 mutation carriers. Maturitas, 2018, 108, 13-17.	2.4	3
52	Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria. Gastrointestinal Endoscopy, 2018, 87, 397-404.e2.	1.0	28
53	High demoralization in a minority of oophorectomized BRCA1/2 mutation carriers influences quality of life. Journal of Psychosomatic Obstetrics and Gynaecology, 2018, 39, 96-104.	2.1	7
54	Increasing awareness and knowledge of lifestyle recommendations for cancer prevention in Lynch syndrome carriers: Randomized controlled trial. Clinical Genetics, 2018, 93, 67-77.	2.0	9

#	Article	IF	Citations
55	Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk. Radiology, 2018, 286, 443-451.	7.3	48
56	NTHL1 and MUTYH polyposis syndromes: two sides of the same coin?. Journal of Pathology, 2018, 244, 135-142.	4.5	63
57	Cancer Risks for PMS2-Associated Lynch Syndrome. Journal of Clinical Oncology, 2018, 36, 2961-2968.	1.6	147
58	The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI. Breast Cancer Research, 2018, 20, 84.	5.0	40
59	An online selfâ€test added to colorectal cancer screening can increase the effectiveness of familial cancer risk assessment without increasing distress. Colorectal Disease, 2018, 20, 897-904.	1.4	2
60	Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD). European Journal of Human Genetics, 2018, 26, 1417-1423.	2.8	20
61	Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress. European Journal of Cancer, 2017, 78, 45-52.	2.8	14
62	Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography. Radiology, 2017, 285, 376-388.	7.3	61
63	Childhood neuroendocrine tumours: a descriptive study revealing clues for genetic predisposition. British Journal of Cancer, 2017, 116, 163-168.	6.4	16
64	Lifestyle Risk Factors for Breast Cancer in BRCA1/2â€Mutation Carriers Around Childbearing Age. Journal of Genetic Counseling, 2017, 26, 785-791.	1.6	6
65	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. European Journal of Human Genetics, 2017, 25, 1246-1252.	2.8	34
66	Self-compassion and climacteric symptoms in postmenopausal BRCA1/2 mutation carriers. Maturitas, 2017, 100, 130.	2.4	0
67	Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Letters, 2017, 403, 159-164.	7.2	37
68	NovelBRCA1andBRCA2Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas. Human Mutation, 2017, 38, 226-235.	2.5	55
69	Colorectal Cancer Risk in Patients With Lynch Syndrome andÂInflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 454-458.e1.	4.4	20
70	Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. Leukemia, 2017, 31, 821-828.	7.2	35
71	A molecular inversion probe-based next-generation sequencing panel to detect germline mutations in Chinese early-onset colorectal cancer patients. Oncotarget, 2017, 8, 24533-24547.	1.8	12
72	Determinants of adherence to recommendations for cancer prevention among Lynch Syndrome mutation carriers: A qualitative exploration. PLoS ONE, 2017, 12, e0178205.	2.5	10

#	Article	IF	Citations
73	Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers. Annals of Oncology, 2016, 27, vi362.	1.2	4
74	Prevalence of germline mutations in the spindle assembly checkpoint gene BUB1B in individuals with earlyâ€onset colorectal cancer. Genes Chromosomes and Cancer, 2016, 55, 855-863.	2.8	30
75	Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunology, Immunotherapy, 2016, 65, 1249-1259.	4.2	67
76	Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. Acta OncolÃ³gica, 2016, 55, 1273-1280.	1.8	62
77	Finding all BRCA pathogenic mutation carriers: best practice models. European Journal of Human Genetics, 2016, 24, S19-S26.	2.8	15
78	Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. Gynecologic Oncology, 2016, 143, 113-119.	1.4	23
79	The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. Cellular Oncology (Dordrecht), 2016, 39, 491-510.	4.4	34
80	Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers. Obstetrics and Gynecology, 2016, 127, 1054-1063.	2.4	21
81	Cardiovascular risk of BRCA1/2 mutation carriers: A review. Maturitas, 2016, 91, 135-139.	2.4	28
82	Health risks for ataxiaâ€telangiectasia mutated heterozygotes: a systematic review, metaâ€analysis and evidenceâ€based guideline. Clinical Genetics, 2016, 90, 105-117.	2.0	143
83	Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. Familial Cancer, 2016, 15, 289-296.	1.9	13
84	Colorectal cancer risk variants at 8q23.3 and 11q23.1 are associated with disease phenotype in APC mutation carriers. Familial Cancer, 2016, 15, 563-570.	1.9	8
85	Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool. European Journal of Medical Genetics, 2016, 59, 116-125.	1.3	125
86	High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCAâ€Mutation Testing without Prior Faceâ€toâ€Face Genetic Counseling. Journal of Genetic Counseling, 2016, 25, 504-514.	1.6	30
87	BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. European Journal of Human Genetics, 2016, 24, 881-888.	2.8	58
88	The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers. Genetics in Medicine, 2016, 18, 405-409.	2.4	15
89	Peer support and additional information in group medical consultations (GMCs) forBRCA1/2mutation carriers: A randomized controlled trial. Acta OncolÃ³gica, 2016, 55, 178-187.	1.8	5
90	Identification of Novel Candidate Genes for Early-Onset Colorectal Cancer Susceptibility. PLoS Genetics, 2016, 12, e1005880.	3.5	52

#	Article	IF	Citations
91	Abstract IA44: Cancer prevention: Dendritic cell enhanced immune responses towards neoantigens in patients with Lynch syndrome. , 2016, , .		0
92	Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Scientific Reports, 2015, 5, 14060.	3.3	67
93	Breast Self-examination Education for BRCA Mutation Carriers by Clinical Nurse Specialists. Clinical Nurse Specialist, 2015, 29, E1-E7.	0.5	11
94	Poor prognosis of constitutive Î³-H2AX expressing triple-negative breast cancers is associated with telomere length. Biomarkers in Medicine, 2015, 9, 383-390.	1.4	17
95	Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: Patients' and professionals' perspectives. Gynecologic Oncology, 2015, 136, 305-310.	1.4	31
96	No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study. Pharmacological Research, 2015, 94, 1-8.	7.1	11
97	Gastric cancer in three relatives of a patient with a biallelic IL12RB1 mutation. Familial Cancer, 2015, 14, 89-94.	1.9	14
98	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
99	Germline deletions in the tumour suppressor gene <scp>FOCAD</scp> are associated with polyposis and colorectal cancer development. Journal of Pathology, 2015, 236, 155-164.	4.5	28
100	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	3.2	479
101	Highlights from the seventh European Multidisciplinary Colorectal Cancer Congress (EMCCC) 2014. Ecancermedicalscience, 2015, 9, 497.	1.1	0
102	How medical choices influence quality of life of women carrying a BRCA mutation. Critical Reviews in Oncology/Hematology, 2015, 96, 555-568.	4.4	22
103	Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1. Gastroenterology, 2015, 149, 897-906.e19.	1.3	70
104	Candidate colorectal cancer predisposing gene variants in Chinese early-onset and familial cases. World Journal of Gastroenterology, 2015, 21, 4136.	3.3	10
105	A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nature Genetics, 2015, 47, 668-671.	21.4	311
106	Improving recognition and referral of patients with an increased familial risk of colorectal cancer: results from a randomized controlled trial. Colorectal Disease, 2015, 17, 499-510.	1.4	10
107	Low prevalence of serrated polyposis syndrome in screening populations: a systematic review. Endoscopy, 2015, 47, 1043-1049.	1.8	28
108	Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer, 2015, 15, 593.	2.6	88

#	Article	IF	Citations
109	Lynch Syndrome Caused by Germline PMS2 Mutations: Delineating the Cancer Risk. Journal of Clinical Oncology, 2015, 33, 319-325.	1.6	177
110	Patient experiences with gene panels based on exome sequencing in clinical diagnostics: high acceptance and low distress. Clinical Genetics, 2015, 87, 319-326.	2.0	23
111	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
112	NTHL1 defines novel cancer syndrome. Oncotarget, 2015, 6, 34069-34070.	1.8	21
113	More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. Familial Cancer, 2014, 13, 143-51.	1.9	33
114	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
115	Germline MUTYH gene mutations are not frequently found in unselected patients with papillary breast carcinoma. Hereditary Cancer in Clinical Practice, 2014, 12, 21.	1.5	4
116	A multiplex method for the detection of serum antibodies against in silico-predicted tumor antigens. Cancer Immunology, Immunotherapy, 2014, 63, 1251-1259.	4.2	6
117	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Journal of Medical Genetics, 2014, 51, 98-107.	3.2	74
118	Easy-to-Use Decision Aids for Improved Cancer Family History Collection and Use Among Oncology Practices. Journal of Clinical Oncology, 2014, 32, 3343-3343.	1.6	5
119	Easyâ€toâ€use online referral test detects most patients with a high familial risk of colorectal cancer. Colorectal Disease, 2014, 16, O26-34.	1.4	12
120	Relevance and efficacy of breast cancer screening inBRCA1andBRCA2mutation carriers above 60 years: A national cohort study. International Journal of Cancer, 2014, 135, 2940-2949.	5.1	13
121	Colorectal cancer risk variants on 11q23 and 15q13 are associated with unexplained adenomatous polyposis. Journal of Medical Genetics, 2014, 51, 55-60.	3.2	21
122	Somatic Mutations in MLH1 and MSH2 Are a Frequent Cause of Mismatch-Repair Deficiency in Lynch Syndrome-Like Tumors. Gastroenterology, 2014, 146, 643-646.e8.	1.3	294
123	Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Annals of Oncology, 2014, 25, 2001-2007.	1.2	26
124	HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 673-679.	2.8	26
125	BRCA1/2 mutation carriers are potentially at higher cardiovascular risk. Critical Reviews in Oncology/Hematology, 2014, 91, 159-171.	4.4	31
126	EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Familial Cancer, 2013, 12, 169-174.	1.9	100

#	Article	IF	Citations
127	Germline Mutations in the Spindle Assembly Checkpoint Genes BUB1 and BUB3 Are Risk Factors for Colorectal Cancer. Gastroenterology, 2013, 145, 544-547.	1.3	86
128	Cost-Effectiveness of Screening Women With Familial Risk for Breast Cancer With Magnetic Resonance Imaging. Journal of the National Cancer Institute, 2013, 105, 1314-1321.	6.3	57
129	Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). European Journal of Human Genetics, 2013, 21, 891-891.	2.8	22
130	Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients. European Journal of Radiology, 2013, 82, 1416-1422.	2.6	18
131	Can we test for hereditary cancer at 18Âyears when we start surveillance at 25? Patient reported outcomes. Familial Cancer, 2013, 12, 675-682.	1.9	15
132	Familial colorectal cancer risk assessment needs improvement for more effective cancer prevention in relatives. Colorectal Disease, 2013, 15, e175-85; discussion p.e185.	1.4	19
133	Identification of germline mutations in the cancer predisposing gene CDH1 in patients with orofacial clefts. Human Molecular Genetics, 2013, 22, 919-926.	2.9	55
134	Focusing on Patient Needs and Preferences May Improve Genetic Counseling for Colorectal Cancer. Journal of Genetic Counseling, 2013, 22, 118-124.	1.6	10
135	Comparability versus statistical correctness. European Journal of Radiology, 2013, 82, e908.	2.6	1
136	Added Value of Family History in Counseling About Risk of BRCA1/2 Mutation in Early-Onset Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2013, 23, 1406-1410.	2.5	4
137	Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling. PLoS ONE, 2013, 8, e55734.	2.5	29
138	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	2.5	23
139	Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome. Journal of Clinical Oncology, 2012, 30, 4409-4415.	1.6	262
140	Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1458-1468.	2.5	79
141	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
142	Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 425-431.	2.8	4
143	Rare variants in XRCC2 as breast cancer susceptibility alleles: TableÂ1. Journal of Medical Genetics, 2012, 49, 618-620.	3.2	49
144	Adequacy of family history taking in ovarian cancer patients: a population-based study. Familial Cancer, 2012, 11, 343-349.	1.9	12

#	Article	IF	Citations
145	DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct. BMC Women's Health, 2012, 12, 12.	2.0	9
146	Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hereditary Cancer in Clinical Practice, 2012, 10, 18.	1.5	33
147	Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial Cancer, 2012, 11, 363-369.	1.9	71
148	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	2.5	11
149	CDH1â€related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. International Journal of Cancer, 2012, 131, 367-376.	5.1	110
150	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	6.4	27
151	Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologistâ€™s initiative. Familial Cancer, 2012, 11, 259-267.	1.9	16
152	Revertant Somatic Mosaicism by Mitotic Recombination in Dyskeratosis Congenita. American Journal of Human Genetics, 2012, 90, 426-433.	6.2	97
153	Rare Mutations in XRCC2 Increase the Risk of Breast Cancer. American Journal of Human Genetics, 2012, 90, 734-739.	6.2	172
154	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	2.5	34
155	Mutation and association analyses of the candidate genes ESR1, ESR2, MAX, PCNA, and KAT2A in patients with unexplained MSH2-deficient tumors. Familial Cancer, 2012, 11, 19-26.	1.9	1
156	9 Genetisch is profetisch?. , 2012, , 91-99.		0
157	Abstract P3-02-09: Cost-effectiveness of screening with additional MRI for women with familial risk for breast cancer without a genetic predisposition. , 2012, , .		0
158	Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome. European Journal of Cancer, 2011, 47, 1407-1413.	2.8	11
159	Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening. European Journal of Cancer, 2011, 47, 1571-1577.	2.8	7
160	Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers. Journal of Clinical Epidemiology, 2011, 64, 1434-1443.	5.0	6
161	PP 73 Prognostic relevance of constitutive expression of Î³-H2AX in triple negative breast cancers. European Journal of Cancer, 2011, 47, S25.	2.8	0
162	Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncology, The, 2011, 12, 49-55.	10.7	232

#	Article	IF	Citations
163	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	5.0	71
164	Constitutive expression of Î³-H2AX has prognostic relevance in triple negative breast cancer. Radiotherapy and Oncology, 2011, 101, 39-45.	0.6	74
165	Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. European Journal of Human Genetics, 2011, 19, 870-874.	2.8	141
166	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	6.4	7
167	Erfelijke darmkanker. Bijblijven (Amsterdam, Netherlands), 2011, 27, 20-26.	0.0	0
168	Shortened time interval between colorectal cancer diagnosis and risk testing for hereditary colorectal cancer is not related to higher psychological distress. Familial Cancer, 2011, 10, 51-57.	1.9	8
169	Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2011, 126, 193-202.	2.5	59
170	A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients. Breast Cancer Research and Treatment, 2011, 130, 425-436.	2.5	17
171	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	3.8	18
172	Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial. BMC Women's Health, 2011, 11, 39.	2.0	14
173	Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Human Mutation, 2011, 32, 407-414.	2.5	137
174	Identification of candidate predisposing copy number variants in familial and earlyâ€onset colorectal cancer patients. International Journal of Cancer, 2011, 129, 1635-1642.	5.1	66
175	Spindle-Assembly Checkpoint and Gastrointestinal Cancer. New England Journal of Medicine, 2011, 364, 1279-1280.	27.0	13
176	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	2.9	68
177	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	2.5	16
178	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	2.9	32
179	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	6.3	40
180	Lynch Syndrome-Associated Extracolonic Tumors Are Rare in Two Extended Families With the Same EPCAM Deletion. American Journal of Gastroenterology, 2011, 106, 1829-1836.	0.4	50

#	Article	IF	Citations
181	Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 653-659.	2.8	17
182	Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2010, 120, 235-244.	2.5	79
183	Reliability of self-reported diagnostic radiation history in BRCA1/2Âmutation carriers. European Journal of Epidemiology, 2010, 25, 103-113.	5.7	4
184	Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2Âyears. Familial Cancer, 2010, 9, 213-220.	1.9	15
185	Constitutional submicroscopic genome imbalances in children with both cancer and a congenital anomaly. Cancer Genetics and Cytogenetics, 2010, 203, 52.	1.0	0
186	EPCAM deletions and heritable MSH2 promoter methylation in Lynch syndrome. Cancer Genetics and Cytogenetics, 2010, 203, 57.	1.0	0
187	Germline epimutation of the tumor suppressor gene PTPRJ in early onset familial colorectal cancer. Cancer Genetics and Cytogenetics, 2010, 203, 59.	1.0	1
188	The epigenetics of (hereditary) colorectal cancer. Cancer Genetics and Cytogenetics, 2010, 203, 1-6.	1.0	33
189	Noonan syndrome, the SOS1 gene and embryonal rhabdomyosarcoma. Genes Chromosomes and Cancer, 2010, 49, 635-641.	2.8	33
190	Improving calculation, interpretation and communication of familial colorectal cancer risk: Protocol for a randomized controlled trial. Implementation Science, 2010, 5, 6.	6.9	9
191	Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. Leukemia, 2010, 24, 242-246.	7.2	85
192	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	21.4	309
193	Psychosocial impact of Von Hippelâ€“Lindau disease: levels and sources of distress. Clinical Genetics, 2010, 77, 483-491.	2.0	35
194	BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. Journal of Clinical Oncology, 2010, 28, 5265-5273.	1.6	166
195	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
196	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2010, 19, 2886-2897.	2.9	60
197	Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	2.5	37
198	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 2010, 47, 436-444.	3.2	495

#	Article	IF	Citations
199	Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. Journal of Medical Genetics, 2010, 47, 464-470.	3.2	165
200	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics, 2010, 6, e1001183.	3.5	85
201	Germline Epigenetic Silencing of the Tumor Suppressor Gene PTPRJ in Early-Onset Familial Colorectal Cancer. Gastroenterology, 2010, 139, 2221-2224.	1.3	46
202	TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. Journal of Medical Genetics, 2010, 47, 421-428.	3.2	254
203	Germline copy number variation and cancer risk. Current Opinion in Genetics and Development, 2010, 20, 282-289.	3.3	115
204	Educational-support groups for BRCA mutation carriers satisfy need for information but do not affect emotional distress. Genetic Counseling, 2010, 21, 423-37.	0.1	17
205	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	2.9	99
206	A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example. BMC Cancer, 2009, 9, 211.	2.6	57
207	The tumor suppressor gene FBXW7 is disrupted by a constitutional t(3;4)(q21;q31) in a patient with renal cell cancer. Cancer Genetics and Cytogenetics, 2009, 195, 105-111.	1.0	28
208	Immunohistochemistry is not an accurate first step towards the molecular diagnosis of MUTYH-associated polyposis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 25-29.	2.8	8
209	Incidence of cancer in first-degree relatives of basal cell carcinoma patients. Archives of Dermatological Research, 2009, 301, 295-299.	1.9	3
210	Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Research and Treatment, 2009, 116, 479-489.	2.5	124
211	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 371-379.	2.5	12
212	Genetic testing for Lynch syndrome in the first year of colorectal cancer: a review of the psychological impact. Familial Cancer, 2009, 8, 325-337.	1.9	17
213	Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Familial Cancer, 2009, 8, 391-397.	1.9	63
214	In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response. Histopathology, 2009, 55, 414-422.	2.9	26
215	Compound heterozygosity for two MSH2 mutations suggests mild consequences of the initiation codon variant c.1A>G of MSH2. European Journal of Human Genetics, 2009, 17, 159-164.	2.8	21
216	Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3â€² exons of TACSTD1. Nature Genetics, 2009, 41, 112-117.	21.4	679

#	Article	IF	Citations
217	Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. British Journal of Cancer, 2009, 100, 266-273.	6.4	392
218	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	6.4	15
219	Plasma pre Î²-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 714-718.	2.4	17
220	Chromosome 8q23.3 and 11q23.1 Variants Modify Colorectal Cancer Risk in Lynch Syndrome. Gastroenterology, 2009, 136, 131-137.	1.3	80
221	A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2genes based on cancer family history. Breast Cancer Research, 2009, 11, R8.	5.0	45
222	Genetic testing offered directly after the diagnosis of colorectal cancer: a pilot study on the reactions of patients. Genetic Counseling, 2009, 20, 317-25.	0.1	9
223	Most Patients with Colorectal Tumors at Young Age Do Not Visit a Cancer Genetics Clinic. Diseases of the Colon and Rectum, 2008, 51, 1249-1254.	1.3	32
224	Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Human Mutation, 2008, 29, 1282-1291.	2.5	782
225	Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Human Mutation, 2008, 29, 1273-1281.	2.5	41
226	In silico analysis of missense substitutions using sequence-alignment based methods. Human Mutation, 2008, 29, 1327-1336.	2.5	181
227	Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Human Mutation, 2008, 29, 1292-1303.	2.5	54
228	Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Human Mutation, 2008, 29, 1265-1272.	2.5	169
229	Assessment of functional effects of unclassified genetic variants. Human Mutation, 2008, 29, 1314-1326.	2.5	93
230	Prediction and assessment of splicing alterations: implications for clinical testing. Human Mutation, 2008, 29, 1304-1313.	2.5	108
231	Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Human Mutation, 2008, 29, 1261-1264.	2.5	79
232	Is early-onset microsatellite and chromosomally stable colorectal cancer a hallmark of a genetic susceptibility syndrome?. International Journal of Cancer, 2008, 122, 796-801.	5.1	11
233	Genomeâ€wide linkage scan in Dutch hereditary nonâ€BRCA1/2 breast cancer families identifies 9q21â€22 as a putative breast cancer susceptibility locus. Genes Chromosomes and Cancer, 2008, 47, 947-956.	2.8	16
234	Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. European Radiology, 2008, 18, 931-938.	4.5	72

#	Article	IF	Citations
235	Costs of breast cancer surveillance in BRCA mutation carriers. European Journal of Cancer, Supplement, 2008, 6, 94-95.	2.2	0
236	Predisposition to colorectal cancer: exploiting copy number variation to identify novel predisposing genes and mechanisms. Cytogenetic and Genome Research, 2008, 123, 188-194.	1.1	11
237	The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited. Annals of Oncology, 2008, 19, 655-659.	1.2	36
238	Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting. American Journal of Surgical Pathology, 2008, 32, 1246-1251.	3.7	112
239	Familial Breast Cancer: Detection of Prevalent High-Risk Epithelial Lesions. , 2008, , 61-71.		2
240	Age at Menarche and Menopause and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 740-746.	2.5	63
241	Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer. British Journal of Cancer, 2007, 96, 1605-1612.	6.4	41
242	Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies. BMC Genomics, 2007, 8, 299.	2.8	26
243	Mapping of constitutional translocation breakpoints in renal cell cancer patients: identification of KCNIP4 as a candidate gene. Cancer Genetics and Cytogenetics, 2007, 179, 11-18.	1.0	21
244	Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Research and Treatment, 2007, 102, 357-363.	2.5	40
245	Detecting Lynch syndrome by pathologists. Verhandlungen Der Deutschen Gesellschaft FÃ¼r Pathologie, 2007, 91, 104-11.	0.5	1
246	Optimizing the detection of hereditary non-polyposis colorectal cancer: An update. Scandinavian Journal of Gastroenterology, 2006, 41, 146-152.	1.5	6
247	Numerous high-risk epithelial lesions in familial breast cancer. European Journal of Cancer, 2006, 42, 2492-2498.	2.8	26
248	A substantial part of the fallopian tube is left after standard prophylactic bilateral salpingo-oophorectomy. International Journal of Gynecological Cancer, 2006, 16, 1940-1944.	2.5	10
249	Unfavorable pathological characteristics in familial colorectal cancer with low-level microsatellite instability. Modern Pathology, 2006, 19, 1624-1630.	5.5	10
250	Factors Affecting Sensitivity and Specificity of Screening Mammography and MRI in Women with an Inherited Risk for Breast Cancer. Breast Cancer Research and Treatment, 2006, 100, 109-119.	2.5	83
251	A DGGE system for comprehensive mutation screening ofBRCA1andBRCA2: application in a Dutch cancer clinic setting. Human Mutation, 2006, 27, 654-666.	2.5	75
252	Characterization of Familial Non-BRCA1/2 Breast Tumors by Loss of Heterozygosity and Immunophenotyping. Clinical Cancer Research, 2006, 12, 1693-1700.	7.0	31

#	Article	IF	Citations
253	Surveillance of women at high risk for hereditary ovarian cancer is inefficient. British Journal of Cancer, 2006, 94, 814-819.	6.4	90
254	Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability. British Journal of Cancer, 2006, 95, 1678-1682.	6.4	12
255	Reply: Familial ovarian screening: how to address abnormal TVU findings and its influence on the efficacy of screening?. British Journal of Cancer, 2006, 95, 1126-1127.	6.4	1
256	Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of â€˜easy to applyâ€™ probability models. British Journal of Cancer, 2006, 95, 757-762.	6.4	13
257	The decision evaluation scales. Patient Education and Counseling, 2005, 57, 286-293.	2.2	52
258	Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients. Familial Cancer, 2005, 4, 115-119.	1.9	60
259	Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. Journal of Medical Genetics, 2005, 42, e20-e20.	3.2	51
260	Cost effectiveness of a new strategy to identify HNPCC patients. Gut, 2005, 54, 97-102.	12.1	78
261	Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). Journal of Medical Genetics, 2005, 42, e54-e54.	3.2	170
262	Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. Journal of Medical Genetics, 2005, 42, 711-719.	3.2	360
263	Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2. Breast Cancer Research, 2005, 7, 1.	5.0	0
264	Randomized Trial of a Shared Decision-Making Intervention Consisting of Trade-Offs and Individualized Treatment Information for BRCA1/2 Mutation Carriers. Journal of Clinical Oncology, 2004, 22, 3293-3301.	1.6	106
265	Chromosome 3 Translocations and Familial Renal Cell Cancer. Current Molecular Medicine, 2004, 4, 849-854.	1.3	31
266	Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clinical Genetics, 2004, 65, 308-316.	2.0	62
267	Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. British Journal of Cancer, 2004, 90, 333-342.	6.4	69
268	Impact ofBRCA1/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer. American Journal of Medical Genetics Part A, 2004, 124A, 346-355.	2.4	64
269	More Differences Between HNPCC-related and Sporadic Carcinomas From the Endometrium as Compared to the Colon. American Journal of Surgical Pathology, 2004, 28, 706-711.	3.7	62
270	Very low incidence of microsatellite instability in rectal cancers from families at risk for HNPCC. Clinical Genetics, 2003, 63, 64-70.	2.0	20

#	Article	IF	Citations
271	High Prevalence of Premalignant Lesions in Prophylactically Removed Breasts From Women at Hereditary Risk for Breast Cancer. Journal of Clinical Oncology, 2003, 21, 41-45.	1.6	136
272	Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes: Effect of sex and the LIPC promoter variant. Diabetes Care, 2003, 26, 427-432.	8.6	50
273	Chromosome 3 translocations and the risk to develop renal cell cancer: a Dutch intergroup study. Genetic Counseling, 2003, 14, 149-54.	0.1	9
274	The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Research, 2003, 63, 8153-7.	0.9	86
275	Atorvastatin, Diabetic Dyslipidemia, and Cognitive Functioning. Diabetes Care, 2002, 25, 1250-1251.	8.6	27
276	Decision Analysis of Prophylactic Surgery or Screening for BRCA1 Mutation Carriers: A More Prominent Role For Oophorectomy. Journal of Clinical Oncology, 2002, 20, 2092-2100.	1.6	87
277	Expression of Type III Hyperlipoproteinemia in Apolipoprotein E2 (Arg158â†'Cys) Homozygotes Is Associated With Hyperinsulinemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 294-299.	2.4	55
278	The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia. Journal of Internal Medicine, 2002, 251, 148-155.	6.0	6
279	High fat intake in hyperlipidaemic patients is related to male gender, smoking, alcohol intake and obesity. Netherlands Journal of Medicine, 2001, 59, 16-22.	0.5	11
280	Corneal arcus: indicator for severity of coronary atherosclerosis?. Netherlands Journal of Medicine, 1999, 55, 184-187.	0.5	9
281	Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis, 1999, 146, 167-174.	0.8	54
282	Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Metabolism: Clinical and Experimental, 1999, 48, 7-14.	3.4	31
283	Hypertension treatment with doxazosin significantly decreases femoral wall thickness in males with hypercholesterolemia and peripheral atherosclerotic disease. Atherosclerosis, 1999, 144, 129-130.	0.8	0
284	High saturated fat intake in hyperlipidemic patients is related to male gender, smoking, alcohol intake and obesity. Atherosclerosis, 1999, 144, 130.	0.8	0
285	Gemfibrozil decreases autoantibodies against oxidized lowâ€density lipoprotein in men with combined hyperlipidaemia. Journal of Internal Medicine, 1998, 243, 355-359.	6.0	8
286	Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. Journal of Internal Medicine, 1998, 244, 143-147.	6.0	15
287	The IGF-I/IGFBP system in congenital partial lipodystrophy. Clinical Endocrinology, 1998, 49, 465-473.	2.4	11
288	Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease. Metabolism: Clinical and Experimental, 1998, 47, 675-680.	3.4	32

#	Article	IF	Citations
289	Growth hormone restores hepatic lipase mRNA levels but the translation is impaired in hepatocytes of hypothyroid rats. Lipids and Lipid Metabolism, 1997, 1345, 172-179.	2.6	6
290	Significance of various parameters derived from biological variability of lipoprotein(a), homocysteine, cysteine, and total antioxidant status. Clinical Chemistry, 1997, 43, 1958-1964.	3.2	41
291	Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity. Leukemia, 1997, 11, 1377-1379.	7.2	60
292	The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. Journal of Internal Medicine, 1997, 241, 151-155.	6.0	1
293	The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. Journal of Internal Medicine, 1997, 241, 151-5.	6.0	0
294	Significance of various parameters derived from biological variability of lipoprotein(a), homocysteine, cysteine, and total antioxidant status. Clinical Chemistry, 1997, 43, 1958-64.	3.2	5
295	Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats. Metabolism: Clinical and Experimental, 1996, 45, 680-685.	3.4	14
296	Hypertriglyceridemia Enhances Monocyte Binding to Endothelial Cells in NIDDM. Diabetes Care, 1996, 19, 1122-1125.	8.6	24
297	Lipoprotein(a) in Patients With Acute Cerebral Ischemia. Stroke, 1996, 27, 1231-1235.	2.0	35
298	Oral physiological magnesium supplementation for 6 weeks with 1 g/d magnesium oxide does not affect increased Lp(a) levels in hypercholesterolaemic subjects. Magnesium Research, 1996, 9, 129-32.	0.5	2
299	LETTERS TO THE EDITOR. Journal of Internal Medicine, 1995, 237, 603-605.	6.0	6
300	Monocytes from patients with combined hypercholesterolemia-hypertriglyceridemia and isolated hypercholesterolemia show an increased adhesion to endothelial cells in vitro: II. Influence of intrinsic and extrinsic factors on monocyte binding. Metabolism: Clinical and Experimental, 1995, 44, 374-378.	3.4	22
301	Growth hormone normalizes hepatic lipase in hypothyroid rat liver. Metabolism: Clinical and Experimental, 1993, 42, 669-671.	3.4	5
302	Hyperglycemia in the acute phase of stroke is not caused by stress.. Stroke, 1993, 24, 1129-1132.	2.0	126
303	The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clinical Endocrinology, 1992, 37, 79-87.	2.4	328
304	Patients with combined hypercholesterolemia-hypertriglyceridemia show an increased monocyte-endothelial cell adhesion in vitro: Triglyceride level as a major determinant. Metabolism: Clinical and Experimental, 1991, 40, 1119-1121.	3.4	34
305	The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. Journal of Internal Medicine, 1990, 228, 261-266.	6.0	37
306	Growth hormone and thyroxine affect lipoprotein metabolism in hypothyroid and hypophysectomized rats. Journal of Endocrinology, 1990, 125, 403-407.	2.6	9

#	Article	IF	Citations
307	Relationship between insulin-like growth factor-I and low-density lipoprotein cholesterol levels in primary hypothyroidism in women. Journal of Endocrinology, 1989, 123, 341-345.	2.6	21
308	Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-Tumor Phenotype Including a Predisposition to Colon and Breast Cancer. SSRN Electronic Journal, 0, , .	0.4	1